An ugly earnings report from a competitor is good news for Abbott Labs
Every weekday the CNBC Investing Club with Jim Cramer holds a “Morning Meeting” livestream at 10:20 a.m. ET. Here’s a recap of Friday’s key moments. Stocks jumped Friday as Wall Street tried to end a turbulent week on a jubilant note. The Dow Jones Industrial Average added more more than 600 points, or 1.6%. The S & P 500 and Nasdaq Composite added 1% and 0.75%, respectively. Among the biggest winners in Friday’s market are companies, such as Club name Stanley Black & Decker , that would see an outsized benefit from a Federal Reserve rate cut. The advances follow an encouraging inflation report Friday morning that keeps the stage set for the U.S. central bank to cut rates at its September policy meeting. With Friday’s surge pushing its week-to-date gains to roughly 10%, we trimmed our Stanley Black & Decker position . In the wreckage of Dexcom ‘s second-quarter earnings report, there’s good news for Club holding Abbott Laboratories . Shares of Dexcom are tanking 40% Friday after the diabetes management firm delivered weaker-than-expected revenue for the April-to-June period and slashed its full-year sales guidance. Dexcom and Abbott compete in the continuous glucose monitor (CGM) market, and we just heard from Abbott that sales of its CGM device, FreeStyle Libre, were up 20% in the second quarter, to $1.6 billion. Dexcom chalked up its issues to factors including salesforce restructurings and higher-than-expected rebate uptake for its new G7 CGM. Whatever the case, the company said it lost some market share. And Abbott may have picked up that lost ground, which is further evidence that its business fundamentals are strong despite the ongoing infant formula legal overhang. Shares of Abbott added 0.75% Friday. Club name Dover picked up a few price-target bumps after the industrial conglomerate’s strong second-quarter earnings report Thursday morning. Mizuho Securities upped its PT to $200 a share from $185 and maintained its buy-equivalent rating — matching our own outlook on the stock. Analysts are upbeat on Dover’s order momentum and noted its biopharma business is “firmly snapping back.” Baird’s new price target on Dover is $219 a share, up from $208 previously. Despite the positive research, shares of Dover were slightly lower Friday. But it’s hardly a concern. It simply looks like a bit of profit-taking after a 5.7% pop Thursday. (Jim Cramer’s Charitable Trust is long SWK, ABT and DOV. See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust’s portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Source link
